ELF · e.l.f. Beauty, Inc.

Current Thesis

e.l.f. Beauty’s international expansion case requires rhode’s European launch to produce measurable sales and the shares to recover their September reference high before losing the August reference level. The operating foundation remains the 2026-08-05 results: fiscal first-quarter net sales of $479.373 million, including $160 million from rhode, and fiscal 2027 sales guidance raised to $1.938–1.968 billion. These are company-reported figures; the inference is that additional distribution can sustain the revised outlook. A reduction below that sales range would contradict the operating case.

Since the 2026-09-05 assessment, analyst support has strengthened while price has weakened. Benzinga records Citi raising its target to $118 on 2026-09-14, Bank of America to $118 on 2026-09-15, B. Riley to $115 on 2026-09-16 and Bernstein to $127 on 2026-09-17. The narrative is accelerating in coverage — this dated sequence replaces the earlier slowdown in target revisions — but it does not establish expanding market participation. Benzinga analyst actions

The measured counterweight is the adjusted close: $96.44 on 2026-09-18, below $109.67 on 2026-09-04 and $101.94 on 2026-08-21. For this dossier, price confirmation means a weekly close above $109.67 before a weekly close below $91.44, the 2026-08-14 reference close. Those are historical market observations used as explicit research thresholds, not demonstrated support or resistance from a complete chart.

Bullish and bearish views on e.l.f. Beauty, Inc.

The model's bull view on e.l.f. Beauty, Inc. (ELF), in brief: Raised guidance supplies operating evidence. The bear view: Favorable revisions lack price confirmation. Both cases follow in full.

Bull Case

• Raised guidance supplies operating evidence. On 2026-08-05, e.l.f. Beauty increased fiscal 2027 sales guidance to $1.938–1.968 billion from $1.835–1.865 billion and adjusted earnings per share guidance to $3.50–3.55 from $3.27–3.32. The expansion thesis loses this support if subsequent guidance falls below the revised ranges.
• Naturium broadens the distribution story. The company’s 2026-09-09 announcement added an exclusive Sephora Mexico debut and expanded Sephora Canada distribution. This establishes additional retail access; it supplies no quantified incremental revenue in the cited announcement. Naturium announcement
• Rhode has a dated rollout. The 2026-08-31 company release schedules Sephora distribution across 19 additional European countries for 2026-09-30. Completion establishes availability; sales disclosure is needed to establish the financial contribution. Company release

Bear Case

• Favorable revisions lack price confirmation. The 2026-09-18 adjusted close of $96.44 remains below the 2026-09-04 close of $109.67 despite the September analyst increases. This observed divergence weakens the near-term price case; a weekly recovery above $109.67 would reverse that assessment.
• Consolidated growth includes acquired revenue. The 2026-08-05 report attributed $160 million of fiscal first-quarter sales to rhode. The reported consolidated growth of 36% cannot establish organic growth for the legacy business; that breakdown is missing from the evidence used here.
• Access does not establish demand. The 2026-08-31 rhode announcement specifies markets and availability, without quantifying European sales. If the subsequent quarterly report provides neither a European sales contribution nor a quantified demand measure, the expansion’s financial benefit remains unproven. Company release

Setup & Price Structure

The supplied adjusted series shows a 2026-09-18 close of $96.44, a three-month price increase of 52.6% and a 14-day relative strength index (RSI) of 38.9. The corresponding RSI was 73.7 on 2026-09-04. These observations describe weaker recent momentum within a positive three-month move; they do not establish a completed base.

The $91.44 close on 2026-08-14 provides the published invalidation reference. The $101.94 close on 2026-08-21 is an intermediate recovery reference, while the $109.67 close on 2026-09-04 defines the price-confirmation threshold. Moving-average values and their slopes are unavailable in the supplied adjusted series, so distance above a rising average cannot be claimed.

The September analyst-action cluster is observable coverage concentration, not a measurement of ownership crowding. The 2026-09-01 Form 4 information identifies an operations executive’s sale under a prearranged Rule 10b5-1 plan; the separately reported chief executive transaction was a gift. Neither establishes discretionary bearish intent. No sufficiently broad retail-sentiment sample or current positioning series supports a crowding verdict.

Catalyst Calendar (next 30 days)

• 2026-09-29 — Brazil retail launch. The 2026-09-15 announcement schedules e.l.f. Cosmetics’ exclusive Sephora Brazil launch for this date. The observable test is whether the announced retail availability begins; revenue contribution remains unquantified. September company-news record
• 2026-09-30 — Rhode European launch. The 2026-08-31 company release schedules online and most-store availability across 19 additional countries. A delay would contradict the announced timetable; completion alone would not prove incremental sales. Company release

The next quarterly earnings date is unconfirmed in the evidence reviewed as of 2026-09-19. The subsequent report remains the financial test of these distribution announcements.

What Would Change Our Mind

Loss of the August reference level would end the published price case: a weekly close below $91.44 would breach the 2026-08-14 adjusted close before the required recovery above $109.67. The threshold is an analytical choice anchored to an observed close; the limited price sample does not establish its statistical reliability.

The operating case would break separately if management reduced fiscal 2027 sales guidance below the $1.938 billion lower bound announced on 2026-08-05. An on-time European rollout followed by no quantified sales evidence would leave the operating thesis unresolved, rather than confirm it. A reported European contribution alongside maintained or increased guidance would strengthen that case.

Correlation Notes

This remains a single-name expansion thesis. The 2026-09-09 Naturium announcement and the scheduled 2026-09-29 and 2026-09-30 launches concern company-specific distribution; they do not establish a broader consumer-sector advance. No matched sector-return sample is available to measure correlation.

Sephora is the shared channel across Naturium’s September expansion and the announced Brazil and European launches. That overlap creates a plausible common distribution dependency, but it does not measure correlated sales outcomes. The available observations are too limited to support a statistical correlation claim.